Related Experiment Video
Updated: Aug 11, 2026
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study
S Sohn1, O Schoeffski, J Prinz
1Chair for Health Management, University of Erlangen-Nuremberg, Lange Gasse 20, DE-90403 Nuremberg, Germany. stefan.sohn@wiso.uni-erlangen.de
Background:
There is little information concerning the costs of psoriasis and patients' quality of life (QoL) in Germany.
Objective:
To obtain data on the annual costs and QoL(to follow in a further publication) of patients with moderate to severe plaque psoriasis.
Methods:
Between October 2003 and February 2004, six office-based dermatologists and eight dermatology outpatient departments retrospectively documented cost-of-illness data from a societal cost perspective in 184 patients over a 12-month period. Patients were stratified into three subgroups according to their treatment scheme.
Results:
Mean total costs amounted to euro 6,709 per patient and year. The mean PASI score was 18.2 and PBSA 28.9%. Annual costs were highest with euro 8,831 in high-need patients. They also showed the highest PASI score (22.2).
Conclusion:
Moderate to severe plaque psoriasis is associated with tremendous costs, particularly in patients not adequately controlled by conventional therapies, while the outcomes of patients were unsatisfactory.
